[1] Kasten MM, Giordano A. pRb and the cdks in apoptosis and the cell cycle[J]. Cell Death Differ, 1998, 5(2): 132-40. [2] Fisher RP, Morgan DO. CAK in TFIIH: crucial connection or confounding coincidence [J] ? Biochim Biophys Acta, 1996, 1288(1):7-10. [3] Rossignol M, Kolb-Cheynel I, Egly JM. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH [J]. EMBO J, 1997, 16(7): 1628-37. [4] 宋海峰,汤仲明.反义药物作用中的"靶二级结构域"[J].药学学报,2001,36(8):585-9.Song HF, Tang ZM. "Target secondary structural motif′ in the action of antisense oligodeoxynucleotides [J]. Acta Pharmaceutica Sin, 2001, 36(8): 585-9. [5] Sugimoto N, Yasumatsu I. A new concept for the design of antisense oligonucleotides based on nucleic acid thermostability [J]. Curr Med Chem Anti-Canc Agents, 2001, 1(1): 95-112. [6] Jaaskelainen I, Honkakoski P, Urtti A. In vitro delivery ofantisense oligonucleotides [J]. Cell Mol Biol Lett, 2002, 7(2): 236-7. [7] Bochar DA, Pan ZQ, Knights R, et al. Inhibition of transcription by the trimeric cyclin-dependent kinase 7 complex [J]. J Biol Chem,1999, 274(19): 13162-6. [8] Song HF, Tang ZM, Yuan SJ, et al. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis [J]. Acta Pharmacol Sin, 2000,21(1): 80-6. [9] 孔伟东,李彦豪,曾庆乐,等.平阳霉素对血管内皮细胞的生长抑制作用和细胞周期的影响[J].第一军医大学学报,2003,23(8):830-2.Kong WD, Li YH, Zeng QL, et al. Effect of pingyangmycin on the growth and cell cycle of human vascular endothelial cells [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(8): 830-2. [10] Peter MF, Graham B, Carol M, et al. Cell cycle target validation: approaches and successes[J]. Targets, 2003, 2(4): 154-61. [11] 陈汉源.细胞周期素D1与癌症[J].第一军医大学学报(J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao), 1999, 19(6): 586-91. [12] Dyson N. The regulation of E2F by pRB-family proteins[J]. Genes Dev, 1998, 12(15): 2245-62. [13] Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases[J]. Trends Pharmacol Sci, 2002, 23(9):417-25. [14] Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators [J]. J Natl Cancer Inst,2000, 92(5): 376-87. [15] Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chkl inhibition by UCN-01 [J]. J Biol Chem, 2002, 277(48): 46609-15. [16] Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs [J]. Trends Mol Med, 2002, 8 (4 Suppl):S32-7. |